RPAM
ALXN

Rhenman & Partners Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40,000
Closed -$6.12M – 101
2021
Q1 		$6.12M Sell
40,000
-80,000
-67% -$12.4M 0.43% 68
2020
Q4 		$18.7M Sell
120,000
-100,000
-45% -$12.9M 1.53% 28
2020
Q3 		$25.2M Buy
220,000
+30,000
+16% +$3.24M 2.24% 9
2020
Q2 		$21.3M Buy
190,000
+30,000
+19% +$3.19M 2.3% 10
2020
Q1 		$14.4M Buy
160,000
+18,681
+13% +$1.83M 2.01% 14
2019
Q4 		$15.3M Sell
141,319
-105,984
-43% -$11.3M 1.67% 19
2019
Q3 		$24.2M Buy
247,303
+44,286
+22% +$4.99M 3.04% 4
2019
Q2 		$26.6M Buy
203,017
+66,551
+49% +$8.58M 2.93% 4
2019
Q1 		$18.4M Sell
136,466
-93,963
-41% -$11.7M 2.16% 18
2018
Q4 		$22.4M Sell
230,429
-12,900
-5% -$1.52M 2.56% 7
2018
Q3 		$33.8M Buy
243,329
+51,466
+27% +$6.46M 3.39% 3
2018
Q2 		$23.8M Sell
191,863
-30,000
-14% -$3.51M 2.44% 9
2018
Q1 		$24.7M Buy
221,863
+70,000
+46% +$8.37M 3.05% 3
2017
Q4 		$18.2M Sell
151,863
-13,137
-8% -$1.6M 2.45% 8
2017
Q3 		$23.1M Buy
165,000
+11,000
+7% +$1.49M 2.96% 5
2017
Q2 		$18.7M Buy
154,000
+42,298
+38% +$4.92M 2.69% 4
2017
Q1 		$13.5M Buy
111,702
+20,000
+22% +$2.58M 2.14% 14
2016
Q4 		$11.2M Sell
91,702
-70,000
-43% -$8.57M 2.15% 12
2016
Q3 		$19.8M Sell
161,702
-61,380
-28% -$7.9M 3.15% 3
2016
Q2 		$26M Buy
223,082
+102,082
+84% +$14.5M 4.63% 1
2016
Q1 		$16.8M Buy
121,000
+21,000
+21% +$3.08M 3.34% 1
2015
Q4 		$19.1M Sell
100,000
-15,000
-13% -$2.62M 2.88% 4
2015
Q3 		$18M Sell
115,000
-17,800
-13% -$3.25M 2.87% 2
2015
Q2 		$24M Buy
132,800
+17,822
+16% +$3.08M 2.88% 4
2015
Q1 		$19.9M Buy
114,978
+70,978
+161% +$12.8M 3.36% 2
2014
Q4 		$8.14M Sell
44,000
-14,000
-24% -$2.59M 2.36% 7
2014
Q3 		$9.62M Sell
58,000
-35,000
-38% -$5.75M 2.82% 4
2014
Q2 		$14.5M Sell
93,000
-18,731
-17% -$2.96M 4.31% 4
2014
Q1 		$17M Buy
111,731
+61,731
+123% +$9.82M 5.1% 2
2013
Q4 		$6.65M Buy
+50,000
New +$6M 2.6% 8

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Rhenman & Partners Asset Management's ALXN Position: Q2 2021 in Review

Rhenman & Partners Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 40,000 shares — an estimated $6.12M sold.

Rhenman & Partners Asset Management first reported a position in ALXN in Q4 2013 and held it in 30 quarters. The position peaked at $33.8M in Q3 2018. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Rhenman & Partners Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 40,000 Alexion Pharmaceuticals shares in Q2 2021, an estimated $6.12M.
  • Rhenman & Partners Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 30 quarters.
  • Rhenman & Partners Asset Management's Alexion Pharmaceuticals position peaked at $33.8M in Q3 2018.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.